December 09, 2016 10:43 PM ET


Company Overview of Applied Genetic Technologies Corporation

Company Overview

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops genetic therapies to treat patients with inherited diseases. Its lead products consist of four ophthalmology development programs across three targets, including X linked retinoschisis (XLRS) that is in a Phase I/II clinical trials for the treatment of an inherited retinal disease; X-linked retinitis pigmentosa (XLRP), which is enrolling patients in a Phase I/II clinical trials; and achromatopsia (ACHM) that is enrolling patients in a Phase I/II clinical trials. Applied Genetic Technologies Corporation has collaboration agreements with Biogen MA, Inc.; 4D Molecular Therapeutics; and Synpromics Limited....

14193 NW 119th Terrace

Suite 10

Alachua, FL 32615

United States

Founded in 1999

53 Employees



Key Executives for Applied Genetic Technologies Corporation

Chief Executive Officer, President and Director
Age: 55
Total Annual Compensation: $464.0K
Chief Financial Officer
Age: 60
Total Annual Compensation: $327.0K
Chief Medical Officer and Vice President
Age: 69
Total Annual Compensation: $381.5K
Chief Business Officer and Vice President
Age: 60
Total Annual Compensation: $314.2K
Chief Scientific Officer
Age: 56
Total Annual Compensation: $400.0K
Compensation as of Fiscal Year 2016.

Applied Genetic Technologies Corporation Key Developments

AGTC Announces Executive Changes

Applied Genetic Technologies Corporation announced the appointment of Michael Goldstein, M.D., M.B.A. as Chief Medical Officer (CMO) effective as of December 1, 2016. Dr. Goldstein will be responsible for leading the company’s clinical trials, providing medical oversight, and contributing to the overall strategic direction of the company. AGTC’s current Vice President and CMO, Jeffrey D. Chulay, M.D., DTM&H, will remain with the company as Executive Director of Clinical Strategy. Prior to joining AGTC, Dr. Goldstein held multiple roles of increasing responsibility with Eleven Biotherapeutics, including as Chief Medical Officer and Vice President of Clinical Research, where he worked with Eleven’s team to bring a novel treatment for dry eye disease from early research to a completed pivotal trial.

Applied Genetic Technologies Corporation Reports Unaudited Earnings Results for the First Quarter Ended September 30, 2016

Applied Genetic Technologies Corporation reported unaudited earnings results for the first quarter ended September 30, 2016. For the quarter the company’s total revenue was $11,806,000 compared to $11,062,000 a year ago. Income from operations was $3,389,000 against loss of $9,213,000 a year ago. Net income was $3,625,000 or $0.20 per basic and diluted share compared to loss of $9,123,000 or $0.53 per basic and diluted share a year ago.

Applied Genetic Technologies Corporation Presents at Stifel 2016 Healthcare Conference, Nov-15-2016 03:45 PM

Applied Genetic Technologies Corporation Presents at Stifel 2016 Healthcare Conference, Nov-15-2016 03:45 PM. Venue: Lotte New York Palace Hotel, New York, New York, United States. Speakers: Sue Washer, President and Chief Executive Officer.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Applied Genetic Technologies Corporation, please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at